Jeffrey Rothman
Founding Chief Science Officer, Head Of Research & Development Oncogenuity Inc.
Seminars
Thursday 10th September 2026
Achieving Allele Specific KRAS G12D Suppression By Obstructing Oncogene Transcription
3:30 pm
- Demonstrating near complete allele specific suppression of KRAS G12D transcription, validated by PCR and confirming precise oncogene shutdown at the source
- Intracellular delivery of oligonucleotide based therapeutics shown directly and indirectly, overcoming one of the major historical barriers for DNA analog modalities
- Debulking tumors in vivo with clear downstream RAS MAPK pathway suppression, establishing strong mechanistic to efficacy alignment in preclinical models
